Skip to main content
Top
Published in: Medical Oncology 5/2016

01-05-2016 | Original Paper

Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma

Authors: Carmen Loquai, Dagmar Dechent, Marlene Garzarolli, Martin Kaatz, Katharina C. Kaehler, Peter Kurschat, Frank Meiss, Annette Stein, Dorothee Nashan, Oliver Micke, Ralph Muecke, Karsten Muenstedt, Christoph Stoll, Irene Schmidtmann, Jutta Huebner

Published in: Medical Oncology | Issue 5/2016

Login to get access

Abstract

Complementary and alternative medicine (CAM) is used widely among cancer patients. Beside the risk of interaction with cancer therapies, interactions with treatment for comorbidities are an underestimated problem. The aim of this study was to assess prevalence of interactions between CAM and drugs for comorbidities from a large CAM usage survey on melanoma patients and to classify herb–drug interactions with regard to their potential to harm. Consecutive melanoma outpatients of seven skin cancer centers were asked to complete a standardized CAM questionnaire including questions to their CAM use and their taken medication for comorbidities and cancer. Each combination of conventional drugs and complementary substances was evaluated for their potential of interaction. 1089 questionnaires were eligible for evaluation. From these, 61.6 % of patients reported taking drugs regularly from which 34.4 % used biological-based CAM methods. Risk evaluation for interaction was possible for 180 CAM users who listed the names or substances they took for comorbidities. From those patients, we found 37.2 % at risk of interaction of their co-consumption of conventional and complementary drugs. Almost all patients using Chinese herbs were at risk (88.6 %). With a high rate of CAM usage at risk of interactions between CAM drugs and drugs taken for comorbidities, implementation of a regular assessment of CAM usage and drugs for comorbidities is mandatory in cancer care.
Literature
1.
go back to reference Molassiotis A, Fernadez-Ortega P, Pud D, et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005;16:655–63.CrossRefPubMed Molassiotis A, Fernadez-Ortega P, Pud D, et al. Use of complementary and alternative medicine in cancer patients: a European survey. Ann Oncol. 2005;16:655–63.CrossRefPubMed
2.
go back to reference Horneber M, Bueschel G, Dennert G, et al. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187–203.CrossRefPubMed Horneber M, Bueschel G, Dennert G, et al. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. Integr Cancer Ther. 2012;11(3):187–203.CrossRefPubMed
3.
go back to reference Micke O, Bruns F, Glatzel M, et al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med. 2009;1:22–30. Micke O, Bruns F, Glatzel M, et al. Predictive factors for the use of complementary and alternative medicine (CAM) in radiation oncology. Eur J Integr Med. 2009;1:22–30.
4.
go back to reference Huebner J, Muenstedt K, Prott FJ, et al. Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care. 2014;9(1):60–3.CrossRefPubMedPubMedCentral Huebner J, Muenstedt K, Prott FJ, et al. Online survey of patients with breast cancer on complementary and alternative medicine. Breast Care. 2014;9(1):60–3.CrossRefPubMedPubMedCentral
5.
go back to reference Ott IM, Muenstedt K, Micke O, et al. Attitude of oncology/haematology nurses from German speaking countries towards complementary and alternative medicine. Trace Elements Electrolyt. 2015;32(2):74–80.CrossRef Ott IM, Muenstedt K, Micke O, et al. Attitude of oncology/haematology nurses from German speaking countries towards complementary and alternative medicine. Trace Elements Electrolyt. 2015;32(2):74–80.CrossRef
6.
go back to reference Conrad C, Muenstedt K, Micke O, et al. Survey of members of the German Society for Palliative Medicine regarding their attitudes towards complementary and alternative medicine for cancer patients. J Cancer Res Clin Oncol. 2014;140(7):1229–37.CrossRefPubMed Conrad C, Muenstedt K, Micke O, et al. Survey of members of the German Society for Palliative Medicine regarding their attitudes towards complementary and alternative medicine for cancer patients. J Cancer Res Clin Oncol. 2014;140(7):1229–37.CrossRefPubMed
7.
go back to reference Trimborn A, Senf B, Muenstedt K, Buentze l, et al. Attitude of employees of a university clinic to complementary and alternative medicine in oncology. Ann Oncol. 2013;24(10):2641–5.CrossRefPubMed Trimborn A, Senf B, Muenstedt K, Buentze l, et al. Attitude of employees of a university clinic to complementary and alternative medicine in oncology. Ann Oncol. 2013;24(10):2641–5.CrossRefPubMed
8.
go back to reference Huebner J, Micke O, Muecke R, et al. User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res. 2014;34:943–8.PubMed Huebner J, Micke O, Muecke R, et al. User rate of complementary and alternative medicine (CAM) of patients visiting a counseling facility for CAM of a German comprehensive cancer center. Anticancer Res. 2014;34:943–8.PubMed
9.
go back to reference Paul M, Davey B, Senf B, et al. Patients with advanced cancer and their usage of complementary and alternative medicine. J Cancer Res Clin Oncol. 2013;130(9):1515–22.CrossRef Paul M, Davey B, Senf B, et al. Patients with advanced cancer and their usage of complementary and alternative medicine. J Cancer Res Clin Oncol. 2013;130(9):1515–22.CrossRef
10.
go back to reference Henf A, Wesselmann S, Huthmann D, et al. Complementary and alternative medicine in German cancer centers. Oncol Res Treat. 2014;37:390–4.CrossRef Henf A, Wesselmann S, Huthmann D, et al. Complementary and alternative medicine in German cancer centers. Oncol Res Treat. 2014;37:390–4.CrossRef
11.
go back to reference Zeller T, Muenstedt K, Stoll C, et al. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol. 2013;139:357–65.CrossRefPubMed Zeller T, Muenstedt K, Stoll C, et al. Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer center. J Cancer Res Clin Oncol. 2013;139:357–65.CrossRefPubMed
12.
go back to reference Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013;37(1):3–17.CrossRefPubMed Bunchorntavakul C, Reddy KR. Review article: herbal and dietary supplement hepatotoxicity. Aliment Pharmacol Ther. 2013;37(1):3–17.CrossRefPubMed
13.
go back to reference Grubbs V, Plantinga LC, Tuot DS, Hedgeman E, Saran R, Saydah S, Rolka D, Powe NR. Americans’ use of dietary supplements that are potentially harmful in CKD. Am J Kidney Dis. 2013;61(5):739–47.CrossRefPubMedPubMedCentral Grubbs V, Plantinga LC, Tuot DS, Hedgeman E, Saran R, Saydah S, Rolka D, Powe NR. Americans’ use of dietary supplements that are potentially harmful in CKD. Am J Kidney Dis. 2013;61(5):739–47.CrossRefPubMedPubMedCentral
14.
go back to reference Loquai C, Dechent D, Garzarolli M et al. Use of Complementary and alternative medicine by patients with melanoma: a multicenter cross-sectional study in Germany (submitted). Loquai C, Dechent D, Garzarolli M et al. Use of Complementary and alternative medicine by patients with melanoma: a multicenter cross-sectional study in Germany (submitted).
18.
go back to reference Cassileth BR, Lucarelli CD. Herb-Drug Interactions in Oncology; London 2003 Cassileth BR, Lucarelli CD. Herb-Drug Interactions in Oncology; London 2003
19.
go back to reference Robinson A, McGrail MR. Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med. 2004;12(2-3):90–8.CrossRefPubMed Robinson A, McGrail MR. Disclosure of CAM use to medical practitioners: a review of qualitative and quantitative studies. Complement Ther Med. 2004;12(2-3):90–8.CrossRefPubMed
20.
go back to reference Saxe GA, Madlensky L, Kealey S, et al. Disclosure to physicians of CAM use by breast cancer patients: findings from the women‘s healthy eating and living study. Integr Cancer Ther. 2008;7(3):122–7.CrossRefPubMedPubMedCentral Saxe GA, Madlensky L, Kealey S, et al. Disclosure to physicians of CAM use by breast cancer patients: findings from the women‘s healthy eating and living study. Integr Cancer Ther. 2008;7(3):122–7.CrossRefPubMedPubMedCentral
21.
go back to reference Elsner T, Muecke R, Micke O, et al. Survey on the worldwide chronic myeloid leukemia advocates network regarding complementary and alternative medicine. J Cancer Res Clin Oncol. 2013;139(6):1025–31.CrossRefPubMed Elsner T, Muecke R, Micke O, et al. Survey on the worldwide chronic myeloid leukemia advocates network regarding complementary and alternative medicine. J Cancer Res Clin Oncol. 2013;139(6):1025–31.CrossRefPubMed
Metadata
Title
Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma
Authors
Carmen Loquai
Dagmar Dechent
Marlene Garzarolli
Martin Kaatz
Katharina C. Kaehler
Peter Kurschat
Frank Meiss
Annette Stein
Dorothee Nashan
Oliver Micke
Ralph Muecke
Karsten Muenstedt
Christoph Stoll
Irene Schmidtmann
Jutta Huebner
Publication date
01-05-2016
Publisher
Springer US
Published in
Medical Oncology / Issue 5/2016
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-016-0764-6

Other articles of this Issue 5/2016

Medical Oncology 5/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine